Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 163

    1.

    New dosing schedules of dasatinib for CML and adverse event management.

    Wong SF.

    J Hematol Oncol. 2009 Feb 23;2:10. Review.

    PMID:
    19236716
    [PubMed - indexed for MEDLINE]
    Free PMC Article
    2.

    Dasatinib dosing strategies in Philadelphia chromosome-positive leukemia.

    Wong SF.

    J Oncol Pharm Pract. 2009 Mar;15(1):17-27. Epub 2008 Aug 27. Review.

    PMID:
    18753186
    [PubMed - indexed for MEDLINE]
    3.

    Once-daily dasatinib for treatment of patients with chronic myeloid leukemia.

    Tyler T.

    Ann Pharmacother. 2009 May;43(5):920-7. Epub 2009 Mar 31. Review.

    PMID:
    19336654
    [PubMed - indexed for MEDLINE]
    4.

    A once-daily dasatinib dosing strategy for chronic myeloid leukemia.

    Bryant G.

    Clin J Oncol Nurs. 2009 Jun;13(3):316-23.

    PMID:
    19502190
    [PubMed - indexed for MEDLINE]
    5.

    Dasatinib: in chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia.

    Keam SJ.

    BioDrugs. 2008;22(1):59-69. Review.

    PMID:
    18215092
    [PubMed - indexed for MEDLINE]
    6.

    Nilotinib: a second-generation tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia.

    Deremer DL, Ustun C, Natarajan K.

    Clin Ther. 2008 Nov;30(11):1956-75. Review.

    PMID:
    19108785
    [PubMed - indexed for MEDLINE]
    8.

    New approved dasatinib regimen available for clinical use.

    Snyder DS.

    Expert Rev Anticancer Ther. 2009 Mar;9(3):285-92. Review.

    PMID:
    19275507
    [PubMed - indexed for MEDLINE]
    9.

    Dasatinib: a review of its use in the treatment of chronic myeloid leukaemia and Philadelphia chromosome-positive acute lymphoblastic leukaemia.

    McCormack PL, Keam SJ.

    Drugs. 2011 Sep 10;71(13):1771-95. doi: 10.2165/11207580-000000000-00000. Review.

    PMID:
    21902298
    [PubMed - indexed for MEDLINE]
    10.

    Dasatinib in imatinib-resistant or imatinib-intolerant chronic myeloid leukemia in blast phase after 2 years of follow-up in a phase 3 study: efficacy and tolerability of 140 milligrams once daily and 70 milligrams twice daily.

    Saglio G, Hochhaus A, Goh YT, Masszi T, Pasquini R, Maloisel F, Erben P, Cortes J, Paquette R, Bradley-Garelik MB, Zhu C, Dombret H.

    Cancer. 2010 Aug 15;116(16):3852-61.

    PMID:
    20564086
    [PubMed - indexed for MEDLINE]
    Free Article
    11.

    Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias.

    Talpaz M, Shah NP, Kantarjian H, Donato N, Nicoll J, Paquette R, Cortes J, O'Brien S, Nicaise C, Bleickardt E, Blackwood-Chirchir MA, Iyer V, Chen TT, Huang F, Decillis AP, Sawyers CL.

    N Engl J Med. 2006 Jun 15;354(24):2531-41.

    PMID:
    16775234
    [PubMed - indexed for MEDLINE]
    Free Article
    12.

    Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia.

    Shah NP, Kantarjian HM, Kim DW, Réa D, Dorlhiac-Llacer PE, Milone JH, Vela-Ojeda J, Silver RT, Khoury HJ, Charbonnier A, Khoroshko N, Paquette RL, Deininger M, Collins RH, Otero I, Hughes T, Bleickardt E, Strauss L, Francis S, Hochhaus A.

    J Clin Oncol. 2008 Jul 1;26(19):3204-12. Epub 2008 Jun 9.

    PMID:
    18541900
    [PubMed - indexed for MEDLINE]
    13.

    Dasatinib 140 mg once daily versus 70 mg twice daily in patients with Ph-positive acute lymphoblastic leukemia who failed imatinib: Results from a phase 3 study.

    Lilly MB, Ottmann OG, Shah NP, Larson RA, Reiffers JJ, Ehninger G, Müller MC, Charbonnier A, Bullorsky E, Dombret H, Brigid Bradley-Garelik M, Zhu C, Martinelli G.

    Am J Hematol. 2010 Mar;85(3):164-70.

    PMID:
    20131302
    [PubMed - indexed for MEDLINE]
    14.

    Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy.

    Hochhaus A, Kantarjian HM, Baccarani M, Lipton JH, Apperley JF, Druker BJ, Facon T, Goldberg SL, Cervantes F, Niederwieser D, Silver RT, Stone RM, Hughes TP, Muller MC, Ezzeddine R, Countouriotis AM, Shah NP.

    Blood. 2007 Mar 15;109(6):2303-9. Epub 2006 Nov 30. Erratum in: Blood. 2007 Sep 1;110(5):1438.

    PMID:
    17138817
    [PubMed - indexed for MEDLINE]
    Free Article
    15.

    Dasatinib for the treatment of Philadelphia chromosome-positive chronic myelogenous leukaemia after imatinib failure.

    Hochhaus A.

    Expert Opin Pharmacother. 2007 Dec;8(18):3257-64. Review.

    PMID:
    18035968
    [PubMed - indexed for MEDLINE]
    16.

    Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase.

    Guilhot F, Apperley J, Kim DW, Bullorsky EO, Baccarani M, Roboz GJ, Amadori S, de Souza CA, Lipton JH, Hochhaus A, Heim D, Larson RA, Branford S, Muller MC, Agarwal P, Gollerkeri A, Talpaz M.

    Blood. 2007 May 15;109(10):4143-50. Epub 2007 Jan 30.

    PMID:
    17264298
    [PubMed - indexed for MEDLINE]
    Free Article
    17.

    Practical management of dasatinib for maximum patient benefit.

    Galinsky I, Buchanan S.

    Clin J Oncol Nurs. 2009 Jun;13(3):329-35. Review.

    PMID:
    19502192
    [PubMed - indexed for MEDLINE]
    18.

    [Clinical profiles of 7 patients with chronic myelogenous leukemia or Philadelphia chromosome-positive acute lymphoblastic leukemia treated with dasatinib].

    Hoshino T, Tahara K, Miyawaki K, Hatsumi N, Takada S, Miyawaki S, Sakura T.

    Rinsho Ketsueki. 2010 Mar;51(3):181-8. Japanese.

    PMID:
    20379112
    [PubMed - indexed for MEDLINE]
    19.

    Efficacy and safety of dasatinib in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blast phase.

    Cortes J, Kim DW, Raffoux E, Martinelli G, Ritchie E, Roy L, Coutre S, Corm S, Hamerschlak N, Tang JL, Hochhaus A, Khoury HJ, Brümmendorf TH, Michallet M, Rege-Cambrin G, Gambacorti-Passerini C, Radich JP, Ernst T, Zhu C, Van Tornout JM, Talpaz M.

    Leukemia. 2008 Dec;22(12):2176-83. Epub 2008 Aug 28.

    PMID:
    18754032
    [PubMed - indexed for MEDLINE]
    20.

    Optimizing treatment with Bcr-Abl tyrosine kinase inhibitors in Philadelphia chromosome-positive chronic myeloid leukemia: focus on dosing schedules.

    Jabbour E, Cortés JE, Kantarjian H.

    Clin Lymphoma Myeloma. 2008 Mar;8 Suppl 3:S75-81. Review.

    PMID:
    19254884
    [PubMed - indexed for MEDLINE]

      Display Settings:

      Format
      Items per page
      Sort by

      Send to:

      Choose Destination

      Supplemental Content

      Find related data

      Write to the Help Desk